Webcast Alert: Isis Pharmaceuticals Holds Webcast to Discuss Clinical Development Plans for ISIS-APOCIIIRx
CARLSBAD, Calif., April 18, 2012 /PRNewswire/ -- Isis
Pharmaceuticals, Inc. (Nasdaq:
ISIS) announces the following webcast:What:
Clinical Development Plans for
Wednesday, April 25, 2012 at 12:00
p.m. ET / 9:00 a.m. PT
Live on the Internet. Simply log onto
our Web site listed above.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.